![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/10\/20261002_Baylor_College_of_Medicine_Technology_and_Modalities-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Baylor College of Medicine<\/p>\n Event Type<\/strong><\/p>\n Publication \/ Peer-Reviewed Study<\/p>\n Modality<\/strong><\/p>\n Single-Cell Transcriptomic Risk Classifier<\/p>\n Asset<\/strong><\/p>\n LR2-High Chemoresistant Signature (Research)<\/p>\n Target<\/strong><\/p>\n FLT3 \/ CDK4\/6 \/ Retinoid Signaling (Nominated Vulnerabilities)<\/p>\n Disease Area<\/strong><\/p>\n Pediatric Acute Myeloid Leukemia<\/p>\n A peer-reviewed pediatric AML study integrates paired diagnosis\u2013relapse single-cell data with larger outcome cohorts to identify rare chemoresistant cell states that improve risk stratification and nominate drug vulnerabilities. The framework is translationally credible, but remains retrospective and is not yet a prospective clinical assay.<\/p>\n The study, published online 2 October 2026, analyzed single-cell RNA sequencing from 33 paired diagnosis\u2013relapse pediatric AML cases and validated risk associations in independent cohorts. A chemoresistant aggregate termed LR2-high identified approximately 20% of patients and was associated with five-year event-free survival below 40%; among 115 known non-transplanted LR2-high patients, reported five-year event-free survival was 16%. Combining resistant-state abundance with cytogenetic risk and measurable residual disease improved outcome prediction. Functional studies nominated vulnerabilities including FLT3, CDK4\/6, retinoid signaling and transcriptional regulators; tamibarotene response prediction correlated with viability across four samples.<\/p>\n Relapse in AML can arise from minority states that are diluted in bulk profiling. Measuring those states at diagnosis could complement cytogenetics and MRD, particularly when high-risk biology is not captured by dominant clones. Yet discovery in 33 paired cases creates overfitting risk, rare populations near five percent challenge assay reproducibility, and treatment\/transplant selection can confound survival associations. The drug-matching experiments are preclinical and small; correlation across four samples cannot define a predictive biomarker. Clinical translation requires a locked classifier, reproducible sampling, turnaround compatible with induction decisions and prospective utility beyond existing risk tools.<\/p>\n Interpretation A: rare resistant states are causal reservoirs and actionable biomarkers. Enrichment at relapse and functional drug sensitivity support this; retrospective design and treatment confounding weaken causality. Interpretation B: the signatures mark broader adverse biology without adding clinically deployable information. Their association with outcome supports prognostic relevance, while incremental multivariable performance argues they are not merely redundant. Prospective validation, standardized assay thresholds and biomarker-matched intervention would distinguish the views.<\/p>\n Pediatric acute myeloid leukemia is a heterogeneous myeloid malignancy in which relapse is the principal cause of treatment failure. Single-cell RNA sequencing can detect minority transcriptional states hidden in bulk samples. Candidate interventions in the paper span kinase, cell-cycle and retinoid pathways; tamibarotene is a selective retinoic-acid-receptor-alpha agonist.<\/p>\n The strongest contribution is not a new drug target but a higher-resolution definition of who may fail standard therapy. If prospective validation holds, resistant-state profiling could refine transplant or trial allocation; current data are insufficient to change treatment on their own.<\/p>\n Signal Importance: 4 of 5. Signal Direction: uncertain. Confidence in Facts: high for published analyses. Confidence in Interpretation: moderate-low. Red-team conclusion: improved retrospective discrimination can disappear with prospective sampling, and transplant-associated survival differences do not prove the classifier should direct transplantation.<\/p>\n","protected":false},"excerpt":{"rendered":" A peer-reviewed pediatric AML study integrates paired diagnosis\u2013relapse single-cell data with larger outcome cohorts to identify rare chemoresistant cell states that improve risk stratification and nominate drug vulnerabilities. The framework is translationally credible, but…<\/p>\n","protected":false},"author":1,"featured_media":3591,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[76,904],"class_list":["post-3573","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-acute-myeloid-leukemia","tag-baylor-college-of-medicine"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3573"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3573\/revisions"}],"predecessor-version":[{"id":3598,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3573\/revisions\/3598"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3591"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3573"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3573"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n